Travel Vaccines Strategic Business Report 2025 | Market to Reach $18.8 Billion by 2030, Driven by Regulatory Requirements for Entry Into Certain Countries - ResearchAndMarkets.com

The "Travel Vaccines - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.

The global market for Travel Vaccines was estimated at US$13.2 Billion in 2024 and is projected to reach US$18.8 Billion by 2030, growing at a CAGR of 6.0% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Travel Vaccines market.

Travel vaccines have emerged as vital safeguards in a globalized world, where the ease of international movement also raises the risk of infectious disease transmission. Vaccines for yellow fever, hepatitis A and B, typhoid, rabies, cholera, and Japanese encephalitis are not only recommended but often mandatory for travelers visiting specific countries. These immunizations protect travelers and host populations alike, acting as essential public health tools in global disease containment.

Heightened awareness following the COVID-19 pandemic has significantly increased the uptake of pre-travel medical consultations and vaccination plans. As governments tighten cross-border health checks, travelers are more willing to comply with immunization schedules. Multilateral health bodies and travel medicine clinics are reinforcing guidelines, and digital vaccine certification systems have been deployed to validate traveler readiness, particularly in higher-risk regions of Africa, Asia, and Latin America.

How Are Technological and Formulation Advances Enhancing Vaccine Uptake?

The field of vaccinology is undergoing significant innovation, with mRNA platforms, thermostable formulations, and combination vaccines being tailored for travel use. These advances are reducing cold chain dependency, extending shelf life, and simplifying dosage schedules-key benefits for last-minute or remote-area travelers. Some travel vaccines now require just one dose or offer oral options, improving compliance and accessibility.

Another key development is the integration of electronic health records and mobile apps that automate reminders and provide guidance based on destination-specific risks. Clinics are offering bundled packages with tailored vaccine plans and digital certificates. Additionally, prefilled syringes, microneedle patches, and intranasal formulations are enhancing administration safety and efficiency, particularly for pediatric and elderly populations.

Which Traveler Segments and Destinations Are Fueling Demand?

Tourists, humanitarian workers, international students, and business travelers to high-risk regions are primary consumers of travel vaccines. The surge in eco-tourism, rural tourism, and adventure travel increases exposure to vector-borne diseases and zoonoses, driving vaccination needs. Additionally, corporate travel to emerging markets and global supply chain expansion has led to a rise in enterprise-funded immunization programs.

The demand is also rising in non-traditional traveler categories such as digital nomads, missionaries, and expatriates, who require long-term or multiple booster doses. Destination-specific health risks and outbreak alerts frequently alter vaccine requirements, prompting last-minute surges in demand at travel clinics. Furthermore, national mandates and health advisories continue to influence both vaccine availability and traveler compliance.

The Growth in the Travel Vaccines Market Is Driven by Several Factors

Expansion in global travel volumes, heightened awareness of region-specific disease risks, and stricter cross-border health protocols are key growth enablers. Advancements in vaccine platforms-including mRNA, conjugate, and recombinant technologies-are increasing the availability and efficacy of travel vaccines.

The rise in adventure, eco-tourism, and off-grid travel is pushing more travelers into regions with higher pathogen exposure, necessitating preemptive immunization. Digital health tools and mobile vaccine passport systems are streamlining pre-travel compliance, encouraging more consistent uptake. Additionally, institutional support from governments and global health organizations, alongside private sector initiatives in workforce protection, are further accelerating market momentum.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Influenza Vaccines segment, which is expected to reach US$9.4 Billion by 2030 with a CAGR of a 5.5%. The Diphtheria Vaccines segment is also set to grow at 4.9% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $3.6 Billion in 2024, and China, forecasted to grow at an impressive 9.4% CAGR to reach $3.8 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Abbott Laboratories, ALK-Abello A/S, AstraZeneca PLC, Bavarian Nordic A/S, CSL Limited and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Scope Of Study:

• Disease Type (Influenza Vaccines, Diphtheria Vaccines, Hepatitis Vaccines, Typhoid & Other Vaccines)
• End-Use (Adult End-Use, Pediatric End-Use)

Key Attributes:

Key Topics Covered:

MARKET OVERVIEW

• Influencer Market Insights
• World Market Trajectories
• Tariff Impact on Global Supply Chain Patterns
• Travel Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
• Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)

MARKET TRENDS & DRIVERS

• Rising International Travel and Cross-Border Movement Drives Demand for Pre-Travel Vaccinations
• Increased Awareness of Endemic Disease Risks in Emerging Destinations Fuels Preventive Vaccine Uptake
• Growth in Business, Educational, and Medical Tourism Supports Volume Demand
• Expanded Inclusion of Yellow Fever, Typhoid, Hepatitis, and Meningococcal Vaccines in Pre-Travel Protocols
• Regulatory Requirements for Entry Into Certain Countries Drive Compliance-Driven Vaccine Demand
• Use of Combination and Single-Dose Formulations Improves Convenience and Reduces Missed Doses
• Growth in Private Clinics and Travel Health Centers Enhances Access to Targeted Immunizations
• Increased Awareness Campaigns by Health Ministries and Airlines Support Preventive Measures
• Seasonal Travel Peaks Correlate With Vaccine Appointment Upticks in Urban Markets
• Availability of Pre-Filled Syringes and Multi-Dose Packs Improves Distribution Efficiency
• Travel Health App Integrations Support Vaccine Reminders and Record Management
• Adoption in Backpacking, Volunteer, and High-Risk Travel Segments Sustains Niche Growth

FOCUS ON SELECT PLAYERS | Some of the 44 companies featured in this Travel Vaccines market report include:

• Abbott Laboratories
• ALK-Abello A/S
• AstraZeneca PLC
• Bavarian Nordic A/S
• CSL Limited
• F. Hoffmann-La Roche AG
• GlaxoSmithKline plc
• Janssen Pharmaceuticals (J&J)
• Merck & Co., Inc.
• Moderna Inc. (if included)
• Novartis AG
• Novavax, Inc.
• Pfizer Inc.
• Qiagen NV
• Sanofi S.A.
• Valneva SE

For more information about this report visit https://www.researchandmarkets.com/r/wf2lkf

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250730249163/en/